Abstract
l-Dopa continues to be the gold drug in Parkinson’s disease (PD) treatment from 1967. The failure to translate successful results from preclinical to clinical studies can be explained by the use of preclinical models which do not reflect what happens in the disease since these induce a rapid and extensive degeneration; for example, MPTP induces a severe Parkinsonism in only 3 days in humans contrasting with the slow degeneration and progression of PD. This study presents a new anatomy and develops preclinical model based on aminochrome which induces a slow and progressive dysfunction of dopaminergic neurons. The unilateral injection of aminochrome into rat striatum resulted in (1) contralateral rotation when the animals are stimulated with apomorphine; (2) absence of significant loss of tyrosine hydroxylase-positive neuronal elements both in substantia nigra and striatum; (3) cell shrinkage; (4) significant reduction of dopamine release; (5) significant increase in GABA release; (6) significant decrease in the number of monoaminergic presynaptic vesicles; (7) significant increase of dopamine concentration inside of monoaminergic vesicles; (8) significant increase of damaged mitochondria; (9) significant decrease of ATP level in the striatum (10) significant decrease in basal and maximal mitochondrial respiration. These results suggest that aminochrome induces dysfunction of dopaminergic neurons where the contralateral behavior can be explained by aminochrome-induced ATP decrease required both for anterograde transport of synaptic vesicles and dopamine release. Aminochrome could be implemented as a new model neurotoxin to study Parkinson’s disease.
Similar content being viewed by others
References
Segura-Aguilar J, Muñoz P, Paris I (2016) Aminochrome as new preclinical model to find new pharmacological treatment that stop the development of Parkinson’s disease. Curr Med Chem 23:346–359. doi:10.2174/0929867323666151223094103
Lindholm D, Mäkelä J, Di Liberto V, Mudò G, Belluardo N, Eriksson O, Saarma M (2015) Current disease modifying approaches to treat Parkinson’s disease. Cell Mol Life Sci. doi:10.1007/s00018-015-2101-1
Olanow Bartus RT, Volpicelli-Daley LA, Kordower JH (2015) Trophic factors for Parkinson’s disease: to live or let die. Mov Disord 30:1715–1724. doi:10.1002/mds.26426
Segura-Aguilar J, Kostrzewa RM (2015) Neurotoxin mechanisms and processes relevant to Parkinson’s disease: an update. Neurotox Res 27:328–354. doi:10.1007/s12640-015-9519-y
Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA (2014) Protective and toxic roles of dopamine in Parkinson’s disease. J Neurochem 129:898–915. doi:10.1111/jnc.12686
Mullin S, Schapira A (2013) α-Synuclein and mitochondrial dysfunction in Parkinson’s disease. Mol Neurobiol 47:587–597. doi:10.1007/s12035-013-8394-x
Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE (2013) α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 73:155–169. doi:10.1002/ana.23746
Ebrahimi-Fakhari D, Wahlster L, McLean PJ (2012) Protein degradation pathways in Parkinson’s disease: curse or blessing. Acta Neuropathol 124:153–172. doi:10.1007/s00401-012-1004-6
Mercado G, Valdés P, Hetz C (2013) An ERcentric view of Parkinson’s disease. Trends Mol Med 19:165–175. doi:10.1016/j.molmed.2012.12.005
Aguirre P, Urrutia P, Tapia V, Villa M, Paris I, Segura-Aguilar J, Núñez MT (2012) The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 25:795–803. doi:10.1007/s10534-012-9525-y
Zafar KS, Siegel D, Ross D (2006) A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 70:1079–1086. doi:10.1124/mol.106.024703
Huenchuguala S, Muñoz P, Zavala P, Villa M, Cuevas C, Ahumada U, Graumann R, Nore BF, Couve E, Mannervik B, Paris I, Segura-Aguilar J (2014) Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction. Autophagy 10:618–630. doi:10.4161/auto.27720
Arriagada C, Paris I, Sanchez de las Matas MJ, Martinez-Alvarado P, Cardenas S, Castañeda P, Graumann R, Perez-Pastene C, Olea-Azar C, Couve E, Herrero MT, Caviedes P, Segura-Aguilar J (2004) On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol Dis 16:468–477. doi:10.1016/j.nbd.2004.03.014
Xiong R, Siegel D, Ross D (2014) Quinone-induced protein handling changes: implications for major protein handling systems in quinone-mediated toxicity. Toxicol Appl Pharmacol 280:285–295. doi:10.1016/j.taap.2014.08.014
Muñoz P, Cardenas S, Huenchuguala S, Briceño A, Couve E, Paris I, Segura-Aguilar J (2015) DT Diaphorase prevents aminochrome-induced alpha-synuclein oligomer formation and neurotoxicity. Toxicol Sci 145:37–47. doi:10.1093/toxsci/kfv016
Segura-Aguilar J, Lind C (1989) On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine: prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chem Biol Interact 72:309–324. doi:10.1016/0009-2797(89)90006-9
Segura-Aguilar J, Diaz-Veliz G, Mora S, Herrera-Marschitz M (2002) Inhibition of DT-diaphorase is a requirement for Mn(III) to produce a 6-OH-dopamine like rotational behaviour. Neurotox Res 4:127–131. doi:10.1080/10298420290015926
Sotomayor R, Forray MI, Gysling K (2005) Acute morphine administration increases extracellular DA levels in the rat lateral septum by decreasing the GABAergic inhibitory tone in the ventral tegmental area. J Neurosci Res 81:132–139. doi:10.1002/jnr.20537
Fried N, Moffat C, Seifert E, Oshinsky M (2014) Functional mitochondrial analysis in acute brain sections from adult rats reveals mitochondrial dysfunction in a rat model of migraine. Am J Physiol Cell Physiol 307:C1017–C1030. doi:10.1152/ajpcell.00332.2013
Herrera-Marschitz M, Arbuthnott G, Ungerstedt U (2010) The rotational model and microdialysis: significance for dopamine signalling, clinical studies, and beyond. Prog Neurobiol 90:176–189. doi:10.1016/j.pneurobio.2009.01.005
Duty S, Jenner P (2011) Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357–1391. doi:10.1111/j.1476-5381.2011.01426.x
Penttinen AM, Suleymanova I, Albert K, Anttila J, Voutilainen MH, Airavaara M (2016) Characterization of a new low-dose 6-hydroxydopamine model of Parkinson’s disease in rat. J Neurosci Res 94:318–328. doi:10.1002/jnr.23708
di Michele F, Luchetti S, Bernardi G, Romeo E, Longone P (2013) Neurosteroid and neurotransmitter alterations in Parkinson’s disease. Front Neuroendocrinol 34:132–142. doi:10.1016/j.yfrne
Paris I, Perez-Pastene C, Cardenas S, Iturriaga-Vasquez P, Muñoz P, Couve E, Caviedes P, Segura-Aguilar J (2010) Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line. Neurotox Res 18:82–92. doi:10.1007/s12640-009-9148-4
Briceño A, Muñoz P, Brito P, Huenchuguala S, Segura-Aguilar J, Paris IB (2015) Aminochrome toxicity is mediated by inhibition of microtubules polymerization through the formation of adducts with tubulin. Neorotox Res. doi:10.1007/s12640-015-9560-x
Divakaruni AS, Paradyse A, Ferrick DA, Murphy AN, Jastroch M (2014) Analysis and interpretation of microplate-based oxygen consumption and pH data. Methods Enzymol 547:309–354. doi:10.1016/B978-0-12-801415-8.00016-3
Muñoz P, Paris I, Sanders LH, Greenamyre JT, Segura-Aguilar J (2012) Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochim Biophys Acta 1822:1125–1136. doi:10.1016/j.bbadis.2012.03.010
Paris I, Muñoz P, Huenchuguala S, Couve E, Sanders LH, Greenamyre JT, Caviedes P, Segura-Aguilar J (2011) Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. Toxicol Sci 121:376–388. doi:10.1093/toxsci/kfr060
Muñoz P, Huenchuguala S, Paris I, Segura-Aguilar J (2012) Dopamine oxidation and autophagy. Parkinsons Dis 2012:920953. doi:10.1155/2012/920953
Segura-Aguila J, Metodiewa D, Welch CJ (1998) Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 1381:1–6. doi:10.1016/S0304-4165(98)00036-1
Schultzberg M, Segura-Aguilar J, Lind C (1988) Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience 27:763–776. doi:10.1016/0306-4522(88)90181-9
Lozano J, Muñoz P, Nore BF, Ledoux S, Segura-Aguilar J (2010) Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity. Chem Res Toxicol 23:1492–1496. doi:10.1021/tx100182a
Segura-Aguilar J, Baez S, Widersten M, Welch CJ, Mannervik B (1997) Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J Biol Chem 272:5727–5731. doi:10.1074/jbc.272.9.5727
Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 324:25–28. doi:10.1042/bj3240025
Dagnino-Subiabre A, Cassels BK, Baez S, Johansson AS, Mannervik B, Segura-Aguilar J (2000) Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o-quinones. Biochem Biophys Res Commun 274:32–36. doi:10.1006/bbrc.2000.3087
Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1097:152–160
Rosengren E, Linder-Eliasson E, Carlsson A (1985) Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 63:247–253. doi:10.1007/BF01252029
Cuevas C, Huenchuguala S, Muñoz P, Villa M, Paris I, Mannervik B, Segura-Aguilar J (2015) Glutathione transferase-M2-2 secreted from glioblastoma cell protects SH-SY5Y cells from aminochrome neurotoxicity. Neurotox Res 27(217–228):429. doi:10.1007/s12640-014-9500-1
Segura-Aguilar J (2015) A new mechanism for protection of dopaminergic neurons mediated by astrocytes. Neural Regen Res 10:1225–1227. doi:10.4103/1673-5374.162750
Cazorla M, Kang UJ, Kellendonk C (2015) Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease. Mov Disord 30:895–903. doi:10.1002/mds.26282
Touchette JC, Breckenridge JM, Wilken GH, Macarthur H (2015) Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons. Neurosci Lett 612:178–184. doi:10.1016/j.neulet.2015.12.028
Ochs SD, Westfall TC, Macarthur H (2005) The separation and quantification of aminochromes using high-pressure liquid chromatography with electrochemical detection. J Neurosci Methods 142:201–208. doi:10.1016/j.jneumeth.2004.08.010
Segura-Aguilar J, Paris I, Muñoz P (2016) The need of a new and more physiological preclinical model for Parkinson’s disease. Cell Mol Life Sci. doi:10.1007/s00018-016-2140-2
Acknowledgments
This work was supported by FONDECYT # 1100165 (JSA), University of Chile ENL014/14 (JSA); ECOS-CONICYT # C10S02 (JSA, RR-V). FONDECYT # 1120443, FONDAP # 15150012 (CC) and FONDECYT postdoctoral fellowship # 3140458 (FJ)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Herrera, A., Muñoz, P., Paris, I. et al. Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson’s disease. Cell. Mol. Life Sci. 73, 3583–3597 (2016). https://doi.org/10.1007/s00018-016-2182-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-016-2182-5